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points were similar: median PFS (2.3 v 2.3 months, hazard ratio: 1.004 
[0.841-1.199]), response rate (4.4% v 5.5%), stable disease (36.0% v 
39.6%), median overall survival (6.7 v 7.2 months, hazard ratio: 0.973 
[0.805-1.176]). Clinical beneﬁt was a composite endpoint based on PS, 
weight, PPI, analgesic consumption, dyspnoea and cough; the primary 
endpoint of clinical beneﬁt analysis was the rate of clinical beneﬁt 
responders, deﬁned as those patients who demonstrated improvement 
in at least one of these parameters, without deterioration in any other 
parameter, and conﬁrmed once at least three weeks later. No signiﬁcant 
difference was observed in the rate of clinical beneﬁt between the vin-
ﬂunine arm (31 responders, 13.1%, 95% CI 9.1-18.0) and the docetaxel 
arm (39 responders, 15.5%, 95% CI 11.3-20.6: c2, p=0.4389). 
Conclusion: Vinﬂunine 320 mg/m2 every 3 weeks was found to be 
similar in terms of efﬁcacy to docetaxel 75 mg/m2 every 3 weeks in 
patients previously treated with a platinum-containing regimen for 
advanced NSCLC patients. Clinical beneﬁt was also comparable for the 
two study treatments. Low, manageable but different toxicity proﬁles 
were observed in either arm allowing a good median relative dose in-
tensity > 98%. Therefore, vinﬂunine offers a new and useful alternative 
for patients suffering from advanced NSCLC in second line setting.
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Background: Platinum-based chemotherapy doublets represent the 
standard ﬁrst-line treatment of patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC), although toxicity is 
common. Several randomized trials trying to assess whether non-plati-
num combinations were as effective as platinum-based ones yielded 
conﬂicting results. Moreover, another not completely solved question 
is whether triplet regimens could be more effective than chemotherapy 
doublets. This 2 x 2 factorial trial aimed at answering both questions: 
(1) the role of replacing cisplatin (P) with vinorelbine (N), (2) the role 
of adding a third agent, ifosfamide (I), in a chemotherapy doublet with 
gemcitabine (G). Primary endpoint was overall survival (OS). Second-
ary endpoints were response rate (RR), progression-free survival (PFS) 
and toxicity.
Methods: Patients with stage IIIB or IV NSCLC were randomly as-
signed to one of four ﬁrst-line regimens: gemcitabine 1250 mg/m2 on 
days 1, 8 plus cisplatin 80 mg/m2 on day 1 (GP); gemcitabine 1250 
mg/m2 on days 1, 8 plus vinorelbine 25 mg/m2 on days 1, 8 (GN); gem-
citabine 1000 mg/m2 on days 1, 8 plus ifosfamide 2 g/m2 on day 1 plus 
cisplatin 80 mg/m2 on day 1 (GIP); gemcitabine 1000 mg/m2 on days 1, 
8 plus vinorelbine 25 mg/m2 on days 1, 8 plus ifosfamide 3 g/m2 on day 
1 (GIN). Treatments were repeated every 3 weeks for a maximum of 6 
cycles. Considering the 2 x 2 trial design, two comparisons have been 
performed: (1) N-containing vs P-containing regimens [GN and GIN vs 
GP and GIP] and (2) I-triplets vs I-non containing doublets [GIN and 
GIP vs GN and GP]. 
Results: From 10/2001 to 07/2006, a total of 433 patients were 
randomized. The patients characteristics were as follows: 72% males, 
with median age of 63 years (range of 29-79), 40% adenocarcinomas, 
71% stage IV and 53% with ECOG performance status of 0. About 
the comparison (1), RR was 25.6 vs 36.3% (p = 0.032), PFS 5.0 vs 6.5 
months (p = 0.239) and OS 11.1 vs 9.8 months [Hazard Ratio (HR) = 
1.04; 95% C.I.: 0.82-1.33; p = 0.719] for N-containing vs P-contain-
ing regimens, respectively. About the comparison (2), RR was 29.1 vs 
32.8% (p = 0.471), PFS 6.5 vs 5.5 months (p = 0.519) and OS 10.8 vs 
9.8 months (HR = 0.95; 95% C.I.: 0.74-1.21; p = 0.705) for I-triplets vs 
I-non containing doublets, respectively. Grade 3-4 anaemia, leucopenia 
and thrombocytopenia were signiﬁcantly more frequent in P-containing 
regimens; only grade 3-4 leucopenia was more common in I-triplets. 
Concerning non-haematological toxicity, only grade 3-4 nausea-vom-
iting was signiﬁcantly increased in P-containing regimens; no other 
statistically signiﬁcant difference in toxicity was observed. 
Conclusions: Results of this unplanned preliminary analysis indicate 
that replacing P with N or the addiction of I to a chemotherapy doublet 
regimen did not improve OS in the treatment of stage IIIB-IV NSCLC 
patients. However, P-containing regimens showed a statistically signiﬁ-
cant advantage in RR over P-free chemotherapy. 
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Background: Chemotherapeutic response rate would be different by 
the ethnic background. This is a randomized prospective trial of three 
cisplatin-based chemotherapeutic regimens in Korean patients with 
advanced non-small-cell lung cancer.
Methods: A total of 333 patients with advanced non-small cell lung 
cancer were randomly assigned to one of the three regimens of 3-
weekly cycle: cisplatin of 60 mg/m2 on day 1 with docetaxel of 75mg/
m2 (DP) or paclitaxel of 130 mg/m2 (TP) on day 1, or gemcitabine of 
1200mg/m2 on day 1 and 8 (GP). After 2~3 cycles of chemotherapy, 
non-responding patients were crossly assigned to the second-line 
monotherapy of either docetaxel or gemcitabine.
Results: There was no signiﬁcant difference in sex, stage, and perfor-
mance status (PS) score, number of cycles and delivered dose inten-
sity between the 3 groups. Three fourths of the patients had stage IV 
disease and one fourth showed ECOG PS score of 2. Mean cycle of 
the ﬁrst-line chemotherapy was 3.4, and the relative dose intensity was 
97%. The overall response rate was 41.8%, with a median survival of 
328 days (95% CI: 271~385) and median progression free survival of 
139 days (95% CI: 111~167 days). The response rate and progression 
free survival did not differ among the 3 groups. The ﬁrst-line treatment 
